Open access · US-GOV
via ClinicalTrials.gov Clinical trial
LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA)
Authors not listed
Sheba Medical Center · 2021
Abstract
Phase IV, 3-armed, prospective, open-label, single-center, Israeli study, examining the response to SARS-CoV-2 vaccination in 30 teriflunomide-, 10 alemtuzumab-treated patients, and 30 age-matched (for the teriflunomide group) untreated MS patients. Treatments will be administered according to common local practice. Demographic, clinical, treatment-related and COVID-19-related data will be collected. Blood samples will be drawn for each participant at baseline (before COVID-19 vaccination), and at 1, 3, 6, (and possibly 12) months post 2nd dose of COVID-19 vaccine. Humoral, B-cell and T-cell responses will be evaluated.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-13 MST
Cite this
APA
Anonymous. (2021). LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA). <em>Sheba Medical Center</em>. https://clinicaltrials.gov/study/NCT05075499
Vancouver
Anonymous. LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA). Sheba Medical Center. 2021.
BibTeX
@misc{anon2021LONGEV,
title = {LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA)},
author = {Anonymous},
journal = {Sheba Medical Center},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Washington University School of Medicine 2019
Open access · US-GOV
Combining Testosterone Therapy and Exercise to Improve Function Post Hip Fracture
IRCCS San Camillo, Venezia, Italy 2021
Open access · US-GOV
Two-Year Prospective Study of Antibody Response and Longevity Post SARS-CoV-2 Vaccine and Their Correlation With Humoral Factors
Istituto Nazionale di Ricovero e Cura per Anziani 2020
Open access · US-GOV
ReportAge-COVID Project: Clinical and Biological Predictors of COVID-19 Disease in Older Patients
UConn Health 2019
Open access · US-GOV
Vaccination Efficacy With Metformin in Older Adults: A Pilot Study
National Institute on Aging (NIA) 2021
Open access · US-GOV
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
National Vaccine and Serum Institute, China 2022
Open access · US-GOV